The primary objective was to demonstrate vaccine efficacy ( VE ) in a per-protocol analysis against likely bacterial CAP ( B-CAP : radiologically confirmed CAP with alveolar consolidation/pleural effusion on chest X-ray , or non-alveolar infiltrates and C-reactive protein 40 g/ml ) ; other protocol-specified outcomes were also assessed .